GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (OTCPK:SYRS) » Definitions » YoY Rev. per Sh. Growth

SYRS (Syros Pharmaceuticals) YoY Rev. per Sh. Growth : -100.00% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Syros Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was -100.00%.

Syros Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Syros Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Syros Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals YoY Rev. per Sh. Growth Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.50 564.91 14.58 -68.64 -70.20

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.55 135.14 -100.00 -100.00 -100.00

Syros Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Syros Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.351-1.178)/ | 1.178 |
=-70.20 %

Syros Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=(Revenue per Share (Q: Sep. 2024 )-Revenue per Share (Q: Sep. 2023 )) / | Revenue per Share (Q: Sep. 2023 )) |
=(0-0.134)/ | 0.134 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (OTCPK:SYRS) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
ARTH LADX SCPX ATXI ISCO TNFA VIRX AXIM MRZM RGBP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0LC7:UK 0S90:Germany
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Website
https://www.syros.com
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Executives
Nancy A Simonian director, 10 percent owner, officer: President & CEO C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk officer: Chief Legal Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421